Management of sarcomas of the uterus

Akiva P. Novetsky, Matthew A. Powell

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Uterine sarcomas are rare malignancies accounting for 8-10% of all uterine malignancies, but are significantly more aggressive and have worse prognosis. Management of uterine sarcomas including leiomyosarcoma (LMS), endometrial stromal sarcoma, high-grade undifferentiated sarcoma and adenosarcoma is reviewed. RECENT FINDINGS: Uterine carcinosarcomas are staged and treated similarly to high-grade epithelial endometrial carcinomas and are no longer considered uterine sarcomas. Gemcitabine/docetaxel with doxorubicin holds promise for the treatment of LMS. A recently developed nomogram was demonstrated to predict disease recurrence in patients with LMS which may allow us to identify a subset of patients who are likely to recur and target this population for adjuvant systemic therapy. Cytogenetic abnormalities have been identified that allow differentiation of endometrial stromal sarcomas from high-grade undifferentiated uterine sarcomas which may be useful in pathologically difficult cases. SUMMARY: Uterine sarcomas are a heterogeneous group of tumors. To date, limited advancements have been made in discovering targeted therapies to these tumors. Chemotherapy with gemcitabine/docetaxel followed by doxorubicin holds promise in the treatment of LMS. Given the rarity of these tumors and the lack of clinical trials to guide management, patients with uterine sarcomas should be encouraged to enroll on clinical trials.

Original languageEnglish (US)
Pages (from-to)546-552
Number of pages7
JournalCurrent Opinion in Oncology
Volume25
Issue number5
DOIs
StatePublished - Sep 2013
Externally publishedYes

Fingerprint

Sarcoma
Uterus
Leiomyosarcoma
docetaxel
gemcitabine
Endometrial Stromal Sarcoma
Neoplasms
Doxorubicin
Adenosarcoma
Clinical Trials
Carcinosarcoma
Nomograms
Health Services Needs and Demand
Therapeutics
Endometrial Neoplasms
Chromosome Aberrations
Recurrence
Drug Therapy

Keywords

  • Adenosarcoma
  • Endometrial stromal sarcoma
  • High-grade undifferentiated sarcoma
  • Leiomyosarcoma
  • Uterine sarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Management of sarcomas of the uterus. / Novetsky, Akiva P.; Powell, Matthew A.

In: Current Opinion in Oncology, Vol. 25, No. 5, 09.2013, p. 546-552.

Research output: Contribution to journalArticle

Novetsky, Akiva P. ; Powell, Matthew A. / Management of sarcomas of the uterus. In: Current Opinion in Oncology. 2013 ; Vol. 25, No. 5. pp. 546-552.
@article{b00d1b77363b45caba6efc45b1ee6813,
title = "Management of sarcomas of the uterus",
abstract = "PURPOSE OF REVIEW: Uterine sarcomas are rare malignancies accounting for 8-10{\%} of all uterine malignancies, but are significantly more aggressive and have worse prognosis. Management of uterine sarcomas including leiomyosarcoma (LMS), endometrial stromal sarcoma, high-grade undifferentiated sarcoma and adenosarcoma is reviewed. RECENT FINDINGS: Uterine carcinosarcomas are staged and treated similarly to high-grade epithelial endometrial carcinomas and are no longer considered uterine sarcomas. Gemcitabine/docetaxel with doxorubicin holds promise for the treatment of LMS. A recently developed nomogram was demonstrated to predict disease recurrence in patients with LMS which may allow us to identify a subset of patients who are likely to recur and target this population for adjuvant systemic therapy. Cytogenetic abnormalities have been identified that allow differentiation of endometrial stromal sarcomas from high-grade undifferentiated uterine sarcomas which may be useful in pathologically difficult cases. SUMMARY: Uterine sarcomas are a heterogeneous group of tumors. To date, limited advancements have been made in discovering targeted therapies to these tumors. Chemotherapy with gemcitabine/docetaxel followed by doxorubicin holds promise in the treatment of LMS. Given the rarity of these tumors and the lack of clinical trials to guide management, patients with uterine sarcomas should be encouraged to enroll on clinical trials.",
keywords = "Adenosarcoma, Endometrial stromal sarcoma, High-grade undifferentiated sarcoma, Leiomyosarcoma, Uterine sarcoma",
author = "Novetsky, {Akiva P.} and Powell, {Matthew A.}",
year = "2013",
month = "9",
doi = "10.1097/CCO.0b013e328363e0ef",
language = "English (US)",
volume = "25",
pages = "546--552",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Management of sarcomas of the uterus

AU - Novetsky, Akiva P.

AU - Powell, Matthew A.

PY - 2013/9

Y1 - 2013/9

N2 - PURPOSE OF REVIEW: Uterine sarcomas are rare malignancies accounting for 8-10% of all uterine malignancies, but are significantly more aggressive and have worse prognosis. Management of uterine sarcomas including leiomyosarcoma (LMS), endometrial stromal sarcoma, high-grade undifferentiated sarcoma and adenosarcoma is reviewed. RECENT FINDINGS: Uterine carcinosarcomas are staged and treated similarly to high-grade epithelial endometrial carcinomas and are no longer considered uterine sarcomas. Gemcitabine/docetaxel with doxorubicin holds promise for the treatment of LMS. A recently developed nomogram was demonstrated to predict disease recurrence in patients with LMS which may allow us to identify a subset of patients who are likely to recur and target this population for adjuvant systemic therapy. Cytogenetic abnormalities have been identified that allow differentiation of endometrial stromal sarcomas from high-grade undifferentiated uterine sarcomas which may be useful in pathologically difficult cases. SUMMARY: Uterine sarcomas are a heterogeneous group of tumors. To date, limited advancements have been made in discovering targeted therapies to these tumors. Chemotherapy with gemcitabine/docetaxel followed by doxorubicin holds promise in the treatment of LMS. Given the rarity of these tumors and the lack of clinical trials to guide management, patients with uterine sarcomas should be encouraged to enroll on clinical trials.

AB - PURPOSE OF REVIEW: Uterine sarcomas are rare malignancies accounting for 8-10% of all uterine malignancies, but are significantly more aggressive and have worse prognosis. Management of uterine sarcomas including leiomyosarcoma (LMS), endometrial stromal sarcoma, high-grade undifferentiated sarcoma and adenosarcoma is reviewed. RECENT FINDINGS: Uterine carcinosarcomas are staged and treated similarly to high-grade epithelial endometrial carcinomas and are no longer considered uterine sarcomas. Gemcitabine/docetaxel with doxorubicin holds promise for the treatment of LMS. A recently developed nomogram was demonstrated to predict disease recurrence in patients with LMS which may allow us to identify a subset of patients who are likely to recur and target this population for adjuvant systemic therapy. Cytogenetic abnormalities have been identified that allow differentiation of endometrial stromal sarcomas from high-grade undifferentiated uterine sarcomas which may be useful in pathologically difficult cases. SUMMARY: Uterine sarcomas are a heterogeneous group of tumors. To date, limited advancements have been made in discovering targeted therapies to these tumors. Chemotherapy with gemcitabine/docetaxel followed by doxorubicin holds promise in the treatment of LMS. Given the rarity of these tumors and the lack of clinical trials to guide management, patients with uterine sarcomas should be encouraged to enroll on clinical trials.

KW - Adenosarcoma

KW - Endometrial stromal sarcoma

KW - High-grade undifferentiated sarcoma

KW - Leiomyosarcoma

KW - Uterine sarcoma

UR - http://www.scopus.com/inward/record.url?scp=84883243250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883243250&partnerID=8YFLogxK

U2 - 10.1097/CCO.0b013e328363e0ef

DO - 10.1097/CCO.0b013e328363e0ef

M3 - Article

C2 - 23942299

AN - SCOPUS:84883243250

VL - 25

SP - 546

EP - 552

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 5

ER -